Last reviewed · How we verify
Emrelis (TELISOTUZUMAB)
Emrelis (generic name: TELISOTUZUMAB) is a Monoclonal antibody drug developed by Abbvie Inc. It is currently FDA-approved (first approved 2025) for non-small cell lung cancer (NSCLC) with high c-Met protein overexpression, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression.
Emrelis binds to the c-Met protein on cancer cells, blocking its growth-promoting signals.
Emrelis is a hepatocyte growth factor receptor inhibitor, classified as an antibody inhibitor. It is being studied for the treatment of progressive, incurable, non-small cell lung cancer, specifically lung non-small cell carcinoma.
At a glance
| Generic name | TELISOTUZUMAB |
|---|---|
| Sponsor | Abbvie Inc |
| Modality | Monoclonal antibody |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 2025 |
Mechanism of action
Telisotuzumab vedotin-tllv is a c-Met-directed antibody drug conjugate (ADC). The antibody is a humanized IgG1κ directed against c-Met, the cell surface receptor for hepatocyte growth factor. The small molecule, MMAE, is a microtubule-disrupting agent, attached to the antibody via a protease cleavable linker. Following binding to c-Met-expressing cells, telisotuzumab vedotin-tllv undergoes internalization and intracellular cleavage of MMAE. MMAE disrupts the microtubule network of actively dividing cells, subsequently inducing cell cycle arrest and apoptotic cell death. Telisotuzumab vedotin-tllv exhibited antitumor activity in xenograft models of NSCLC.
Approved indications
- non-small cell lung cancer (NSCLC) with high c-Met protein overexpression
- locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression
Common side effects
- Peripheral neuropathy
- Fatigue
- Peripheral edema
- Decreased appetite
- ILD/pneumonitis
- Pneumonia
- Nausea
- Constipation
- Vomiting
- Blurred vision
- Keratitis
- Glucose increased
Drug interactions
- Strong CYP3A Inhibitors
- Strong CYP3A Inhibitors
Key clinical trials
- A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (PHASE2)
- A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer (PHASE2)
- A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma (PHASE2,PHASE3)
- A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer (PHASE2,PHASE3)
- A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (PHASE3)
- A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease (PHASE2)
- A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer (PHASE2,PHASE3)
- A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Emrelis CI brief — competitive landscape report
- Emrelis updates RSS · CI watch RSS
- Abbvie Inc portfolio CI
Frequently asked questions about Emrelis
What is Emrelis?
How does Emrelis work?
What is Emrelis used for?
Who makes Emrelis?
What is the generic name of Emrelis?
When was Emrelis approved?
What development phase is Emrelis in?
What are the side effects of Emrelis?
Related
- Manufacturer: Abbvie Inc — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for non-small cell lung cancer (NSCLC) with high c-Met protein overexpression
- Indication: Drugs for locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing